Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axovant Sciences Ltd (AXGT)

Axovant Sciences Ltd (AXGT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 168,116
  • Shares Outstanding, K 22,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,070 K
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.34
  • Number of Estimates 4
  • High Estimate -0.70
  • Low Estimate -1.91
  • Prior Year -3.84
  • Growth Rate Est. (year over year) +65.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.98 +47.79%
on 06/17/19
8.52 -13.62%
on 06/21/19
+2.24 (+43.75%)
since 06/14/19
3-Month
3.81 +93.18%
on 06/11/19
9.60 -23.33%
on 04/29/19
-1.12 (-13.21%)
since 04/15/19
52-Week
3.81 +93.18%
on 06/11/19
21.68 -66.05%
on 07/16/18
-14.00 (-65.54%)
since 07/13/18

Most Recent Stories

More News
Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know

Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.

AXGT : 7.36 (-0.27%)
Will Axovant Sciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Axovant Sciences.

AXGT : 7.36 (-0.27%)
Sarepta Stock Up Almost 40% This Year So Far: Here's Why

Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

SRPT : 156.91 (+0.52%)
AYTU : 1.77 (-0.56%)
BMRN : 83.99 (+1.25%)
AXGT : 7.36 (-0.27%)
Perrigo Completes Ranir Acquisition, Raises '19 Guidance

Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.

BDSI : 3.91 (-3.93%)
PETQ : 35.24 (+2.32%)
AXGT : 7.36 (-0.27%)
PRGO : 51.50 (-0.50%)
Are Options Traders Betting on a Big Move in Axovant (AXGT) Stock?

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

AXGT : 7.36 (-0.27%)
bluebird's Zynteglo Gets EU Conditional Marketing Approval

bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype....

ANIK : 40.34 (+0.72%)
BLUE : 135.75 (+2.34%)
AXGT : 7.36 (-0.27%)
AGTC : 3.80 (+3.54%)
Fibrocell Up on FDA Designation for Gene Therapy Candidate

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

ANIK : 40.34 (+0.72%)
XON : 7.49 (-1.96%)
AXGT : 7.36 (-0.27%)
FCSC : 1.87 (+1.08%)
Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

ANIK : 40.34 (+0.72%)
AXGT : 7.36 (-0.27%)
AGTC : 3.80 (+3.54%)
MNK : 8.42 (-1.98%)
Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?

Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.

ANIK : 40.34 (+0.72%)
AXGT : 7.36 (-0.27%)
AGTC : 3.80 (+3.54%)
EPZM : 13.65 (-0.51%)
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business

Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.

ANIK : 40.34 (+0.72%)
DVAX : 4.04 (+0.25%)
AXGT : 7.36 (-0.27%)
AGTC : 3.80 (+3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AXGT with:

Business Summary

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease...

See More

Key Turning Points

2nd Resistance Point 7.59
1st Resistance Point 7.48
Last Price 7.36
1st Support Level 7.25
2nd Support Level 7.13

See More

52-Week High 21.68
Fibonacci 61.8% 14.85
Fibonacci 50% 12.74
Fibonacci 38.2% 10.64
Last Price 7.36
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar